Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that CD20 + status confers therapeutic sensitivity to Gemcitabine, Oxaliplatin, Rituximab in patients with Non-Hodgkin Lymphoma.
The Republic of Ireland's Health Service Executive (HSE) has approved rituximab in combination with gemcitabine and oxaliplatin for reimbursement as a treatment option for the treatment of relapsed or refractory CD20 positive diffuse large B cell lymphoma in patients ineligible for stem cell transplant.
This statement is based on a regulatory approval from the Health Service Executive:
Relapsed or refractory CD20 positive diffuse large B cell lymphoma in patients ineligible for stem cell transplant.